Oculis

• Oculis, a Swiss neuro-ophthalmic diseases-focused company listed on US Nasdaq and Nasdaq Iceland, successfully raised USD 110 million (excluding greenshoe) in an oversubscribed equity financing
• Early October, the Company announced the advancement of Privosegtor, a first in-class neuroprotective candidate, into a registrational programme for neuro-ophthalmology indications following a positive meeting with the US FDA
• Oculis sold 5,432,098 shares (excluding greenshoe) at USD 20.25 per share, representing a discount of c. 6%  versus the pre-announcement close on the US Nasdaq line, through a combined underwritten offering and registered direct offering
• Oculis intends to use the net proceeds to advance and accelerate the development of its novel neuroprotective clinical candidate, Privosegtor in AON and NAION
• Van Lanschot Kempen acted as Co-Manager and has supported Oculis since it listed on US Nasdaq through a demerger with LSP-backed SPAC EBAC in 2023

• Oculis is a global biopharmaceutical company focused on developing innovative treatments for neuro-ophthalmic conditions with significant unmet medical needs
• Its late-stage pipeline includes Privosegtor for optic neuropathies, OCS-01 as a potential first non-invasive eye drop for diabetic macular edema, and Licaminlimab, an anti-TNFα eye drop for dry eye disease and uveitis
• Headquartered in Switzerland with operations in the US and Iceland, Oculis is listed on Nasdaq (OCS) and XICE (OCS)

In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Joint Bookrunner in the SEK 672 million Capital Increase by Hansa Biopharma
• Joint Bookrunner in the USD 345 million Capital Increase by uniQure
• Joint Bookrunner in the secondary sell-down of existing BioArctic shares for SEK 720 million
• Financial Adviser to Galapagos in the sale of a portfolio of oncology and immunology programmes to Onco3R
• Co-Manager in the USD 748 million Capital Increase by Abivax
• Financial Adviser in MaaT Pharma’s €38 million venture debt facility from the European Investment Bank
• Joint Bookrunner in the USD 201 million Capital Increase by Pharvaris
• Lead Manager in the USD 345 million Capital Increase by Merus
• Co-Placement Agent in DBV Technologies’ up to USD 307 million financing
• Placement Agent in MaaT Pharma’s €13 million capital increase
• Sole Financial Adviser in Pharming’s SEK 725 million public takeover of Abliva
• Sole Financial Adviser in GENFIT’s royalty financing up to €185 million
• Sole Financial Adviser in IO Biotech’s c. €58 million loan facility from the European Investment Bank
• Financial Adviser in the USD 479 million US Public Offering by NewAmsterdam Pharma
• Sole Financial Adviser to SNIPR Biome in securing a €20 million venture debt facility from the European Investment Bank